Rossari Biotech delivers strong performance in Q2FY2022 triggered by uptick in all the segment & recent acquisitions | Q2 FY22 4 Point Result Analysis & Earning Call

The company has delivered strong topline & bottom line growth aided by strong growth momentum across all segments as well as recent acquisitions. But Margins tumbled due to extremely heavy inflationary pressure across segments

Please find attached for detailed analysis.